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ackground: The effect of climate change and its effects on vegetation growth, and consequently on rhinitis,
re uncertain.
bjective: To examine between- and within-country associations of climate measures and the normalized
ifference vegetation index with intermittent and persistent rhinitis symptoms in a global context.
Methods: Questionnaire data from 6- to 7-year-olds and 13- to 14-year-olds were collected in phase 3 of the
International Study of Asthma and Allergies in Childhood. Associations of intermittent (>1 symptom report
but not for 2 consecutive months) and persistent (symptoms for 2 consecutive months) rhinitis symptom
prevalences with temperature, precipitation, vapor pressure, and the normalized difference vegetation index
were assessed in linear mixed-effects regression models adjusted for gross national income and population
density. The mean difference in prevalence per 100 children (with 95% conﬁdence intervals [CIs]) per
interquartile range increase of exposure is reported.
Results: The country-level intermittent symptom prevalence was associated with several country-level
climatic measures, including the country-level mean monthly temperature (6.09C; 95% CI, 2.06e
10.11C per 10.4C), precipitation (3.10 mm; 95% CI, 0.46e5.73 mm; per 67.0 mm), and vapor pressure
(6.21 hPa; 95% CI, 2.17e10.24 hPa; per 10.4 hPa) among 13- to 14-year-olds (222 center in 94 countries).
The center-level persistent symptom prevalence was positively associated with several center-level cli-
matic measures. Associations with climate were also found for the 6- to 7-year-olds (132 center in 57
countries).
Conclusion: Several between- and within-country spatial associations between climatic factors and inter-
mittent and persistent rhinitis symptom prevalences were observed. These results provide suggestive evi-
dence that climate (and future changes in climate) may inﬂuence rhinitis symptom prevalence.
 2014 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.Introduction
The prevalence of allergic rhinitis is increasing in most coun-
tries.1 Environmental factors are suspected of being important
contributing inﬂuences. There is now considerable evidence that
climate change is measurably altering the timing, distribution,dstraße 1, Neuherberg D-85764,
he Canadian Institutes of Health
anada Graduate Scholarship). Ms
nt of Health and the Natural
sthma & Immunology. Published by Equality, and quantity of allergenic plants and aeroallergens,2,3 the
primary risk factors for allergic rhinitis. Such changes are occurring
via meteorologic factors and through interactions with greenhouse
gases. For example, ragweed in an urban site with higher temper-
ature and carbon dioxide concentrations, similar to those associated
with projected climate change, grew faster, ﬂowered earlier, and
produced signiﬁcantly greater above-ground biomass and ragweed
pollen compared with ragweed grown in a rural area.4 Allergic re-
sponses may also be heightened by air pollutants acting directly on
the individual and/or through interactions with allergens.5
Previously, allergic rhinitis symptoms were classiﬁed as sea-
sonal or perennial based on the timing of allergen exposure.lsevier Inc. All rights reserved.
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reﬂects a patient’s true experiences.6 An improved classiﬁcation
system, which categorizes rhinitis symptoms as intermittent or
persistent, is applicable worldwide, better suits a patient’s needs,
and is now being recommended.7 Intermittent and persistent
rhinitis are not synonymous with seasonal and perennial rhinitis
and may be differentially associated with risk factors.8 Studies that
assess how climatic factors may inﬂuence these 2 types of rhinitis
and associated diseases are of interest9 and may provide in-
dications as to the potential effects of future climate change.
One way to examine such associations is through the use of
temporal data, as has been done in limited-area studies.10e13 How-
ever, this approach is not currently feasible on a global scale. Alter-
natively, spatial associations can be examined. The International
Study of Asthma and Allergies in Childhood (ISAAC) is unique in its
global scope and is well suited to assess spatial associations between
disease and ecologic measures of exposure, such as climate. ISAAC
Phase One reported a suggestive role for long-term climatic condi-
tions on asthma and atopic eczema symptom prevalences in West-
ern Europe (57 centers in 12 countries).14 No signiﬁcant associations
were found with allergic rhinitis symptom prevalence. The current
study extends this work by taking advantage of the substantially
larger ISAAC Phase Three data set and the newly adopted rhinitis
classiﬁcations. Speciﬁcally, we aimed to assess spatial associations
between the prevalence of intermittent and persistent rhinitis
symptoms with climate and vegetation in a global context.
Methods
Study Population
The rationale and methods for ISAAC Phase Three have been
previously published.15 The current analysis is limited to ISAAC
centers that collected valid data on monthly rhinitis symptoms:
222 centers in 94 countries for 13- to 14-year-olds and 135 centers
in 59 countries for 6- to 7-year-olds. A diagram summarizing data
availability is provided in eFigure 1. All collaborating centers ob-
tained ethical approval from their local ethics committee or board.
Letters describing the survey were sent to parents of all children.
Parental completion of the questionnaire for the 6-to 7-year-olds
implied consent. For the older age group, passive consent for the
teenager to complete their own questionnaire at school was used
by most centers.
Health Outcomes
Monthly data on rhinitis symptoms were collected via stan-
dardized parent-completed (for children 6e7 years of age) or
child-completed (for children 13e14 years of age) ISAAC ques-
tionnaires (protocols available on the ISAAC website; http://isaac.
auckland.ac.nz/). Individuals were asked to indicate if in the last
12 months they (or their child) had experienced a problem with
sneezing or a runny or blocked nose when they (or their child) did
not have a cold or ﬂu. Subsequent questions asked whether this
nose problem was accompanied by itchy eyes (at any time in the
last 12 months) and in which of the past 12 months this nose
problem occurred. Using the monthly data collected from the last
of these questions, we calculated the prevalences of intermittent
(at least 1 symptom report but not for 2 consecutive months) and
persistent (symptoms for at least 2 consecutive months) rhinitis
symptoms per center. Any apparent inconsistencies between stem
and subsequent branch questions were accepted and not changed.
Environmental Factors and Covariates
Data on monthly mean daily temperature, total precipitation,
and vapor pressure, averaged for 1991e2000 for 0.5  0.5
grids (approximately 3,025 km2), were obtained from theIntergovernmental Panel on Climate Change Data Distribution cen-
ter.16,17 Normalized difference vegetation index (NDVI) data for 2005
were obtained from the Global Land Cover Facility at a resolution of
0.07 on a 16-day basis and averaged permonth.18,19 NDVI data range
from 1 (water) to þ1 (dense vegetation), with values close to
0 indicating barren areas of rock, sand, or snow. Using the monthly
data on temperature, precipitation, vapor pressure, and NDVI, we
calculated the mean, maximum, minimum, SD, and maximal dif-
ference (difference between the monthly maximum and minimum)
of monthly measurements for each factor. Data on gross national
income (GNI) per capita were obtained from the World Bank (Atlas
Method 2003).20 When missing, GNI data were imputed using in-
formation from the Central Intelligence Agency World Fact Book
(2003) (7 countries).21 Population density data for 2005 were ob-
tained from the Socioeconomic Data and Applications center.22
Centers were classiﬁed into 5 climate types according to the Köp-
pen climate classiﬁcation system (snow/polar, equatorial, arid, warm
temperate with dry winter, and warm temperate fully humid).23
The assignment of environmental variables to the centers has
been previously described.24 Brieﬂy, coordinates for the study
population were assigned to a 0.1  0.1 square and compared
with the 8 surrounding 0.1  0.1 squares (each square covers
approximately 121 km2). Of these 9 squares, the one with the
highest population density was considered the center grid and used
for mapping. Climate data were mapped to this single coordinate.
For population density and NDVI, themean values of the center grid
and 8 surrounding grids (each sized 0.07  0.07, approximately
59 km2) were used. Because the resolution of the NDVI data
(0.07  0.07) is not the same as used during the original geo-
coding of the centers (0.1  0.1), the sizes of the grids used for
mapping the environmental factors differ. For climate, population
density, and NDVI data, which were available at the center level,
country-level means were calculated,25 which may not necessarily
represent the true mean of a country. Data on GNI per capita were
only available at the country level.Analytic Strategy
Correlations between center-level variables were assessed using
Spearman correlation coefﬁcients because not all variables were
normally distributed. Linear regression mixed models, which allow
consideration of the hierarchical structure of the data, were used to
assess associations between the prevalence of intermittent and
persistent rhinitis symptoms with the mean, maximum, minimum,
SD, and maximal difference of monthly measurements of temper-
ature, precipitation, vapor pressure, and NDVI (as implemented in
the lme4 package26 in the statistical program R, version 3.0.1).27
Fully adjusted models included the exposure of interest, GNI per
capita, population density, and climate type. Furthermore, all
models included country as a random intercept and ﬁxed effects for
both the center- and country-level representation of each explan-
atory variable, except for GNI per capita, whichwas available only at
the country level. GNI per capita was included in the models
because it was associated with the prevalence of atopic symptoms
in worldwide analyses.28 Including a random intercept for country,
to allow the prevalence rates in countries to deviate from the esti-
mated overall prevalence to avoid spurious results, is important.14
In sensitivity analyses, models were further adjusted for air
pollution (particulate matter with aerodynamic diameters <2.5 m/m
and nitrogen dioxide; data sources and assignment to centers have
been previously described)24 and mutually adjusted for mean
vegetation in themodels estimating the effects of the climatic factors
and mean temperature, precipitation, and vapor pressure in the
models estimating the effects of vegetation.
Between-country effects are presented as the mean difference
in country-level prevalence (per 100 children) associated with
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95% conﬁdence intervals (CIs). For countries with more than 1
participating center, the mean difference in center-level prevalence
(per 100 children) associated with a 1-unit increase in center-level
exposure were also estimated (within-country effects). All analyses
were conducted using the statistical program R, version 3.0.1.27Results
Distribution of Intermittent and Persistent Rhinitis Prevalences
For the centers with 13- to 14-year-olds, the mean center
prevalence for intermittent rhinitis was highest in equatorial re-
gions (mean prevalence, 20.0), was lowest in centers with snow/
polar climates (mean prevalence, 8.9), and varied signiﬁcantly by
climate type (analysis of variance P < .01; Table 1). There was less
variation by climate type for persistent symptoms (highest inwarm
temperate fully humid regions [mean prevalence, 16.1] and lowest
in arid climates [mean prevalence, 11.9]; analysis of variance
P ¼ .04).
Center-speciﬁc sample sizes and intermittent and persistent
symptom prevalences are reported in eTables 1 and 2 for the 13- to
14-year-olds and 6- to 7-year-olds, respectively. Figures 1 and 2
depict the global distribution of intermittent and persistent
symptom prevalence, respectively, for the centers with older age
groups.Distribution and Correlation of Environmental Factors
Characteristics of modeled variables for the 13- to 14-year-olds
are given in Table 2. All 3 measures of mean climatic variables were
positively correlated with intermittent rhinitis prevalence. The
prevalence of persistent rhinitis was negatively correlated with
mean temperature. GNI per capita was negatively correlated with
intermittent rhinitis prevalence, mean temperature, and vapor
pressure and positively correlated with persistent rhinitis preva-
lence andmean NDVI. Population density was negatively correlated
with mean NDVI and positively correlated with mean temperature
and vapor pressure. Positive correlations were observed among all
climatic factors. Mean precipitation was positively correlated with
mean vegetation. Correlations were similar for the centers with
younger age groups, although for persistent rhinitis there was a
positive association with precipitation and no evidence of an as-
sociation with mean temperature. Correlations among different
measures of the same climatic factor were also examined. For the
centers with older age groups, mean temperature was positively
correlated with minimum and maximum temperature and nega-
tively correlated with measures of variability. Mean vapor pressure
was positively correlated with the minimum, maximum, and SD
and negatively correlated with the maximal difference. Mean pre-
cipitation and vegetation were positively correlated with all other
measures of precipitation and vegetation, respectively.Table 1
Intermittent and persistent rhinitis symptom prevalence by climate type for the
centers with 13- to 14-year-olds (222 centers)
Climate type No. of
centers
Intermittent rhinitis Persistent rhinitis
Mean (SD) Range Mean (SD) Range
Snow/polar 12 8.9 (8.0) 0.4e22.4 14.0 (9.3) 3.4e28.3
Arid 23 13.3 (10.3) 0.1e45.4 11.9 (6.0) 1.4e25.6
Equatorial 64 20.0 (11.0) 0.0e49.5 12.9 (8.5) 0e33.8
Warm temperate
with dry winter
21 9.5 (4.0) 3.5e18.6 14.6 (7.0) 3.1e26.8
Warm temperate
fully humid
102 15.4 (7.8) 0.0e44.9 16.1 (7.1) 1.1e32.1Associations Between Rhinitis Symptoms and Environmental Factors
Between-country associations (mean differences in country-
level prevalence per 100 children associated with a 1-unit in-
crease in country-level exposure) for the fully adjusted models for
the centers with 13- to 14-year-olds are presented in Table 3.
Intermittent symptom prevalence was positively associated with
the mean and minimum monthly temperature and negatively
associated with the maximal difference in monthly temperature.
Intermittent symptom prevalence was also positively associated
with the mean, maximum, SD, and maximal difference of monthly
precipitation measurements and the mean, maximum, and mini-
mum monthly vapor pressure measurements. Four of the 10 sig-
niﬁcant associations observed for the centers with older age groups
were also signiﬁcant for the centers with younger age groups
(eTable 3). Persistent symptom prevalence was not associated with
any climatic variable in the fully adjusted models. Confounder-
adjusted risk estimates for vegetation were elevated but nonsig-
niﬁcant for both outcomes.
For the 13- to 14-year-old age group, 37 countries hadmore than
1 participating center (165 centers in total). These centers were
used to assess the mean difference in center-level prevalence per
100 children associated with a 1-unit increase in center-level
exposure (Table 4). Within-country positive associations were
observed between intermittent symptom prevalence and mean
monthly temperature and the SD of monthly vapor pressure mea-
surements. Further positive associations were also observed be-
tween persistent symptom prevalence and mean and maximum
monthly temperature and the mean, maximum, minimum, and SD
of monthly vapor pressure measurements. When the within-
country analyses were replicated in the 6- to 7-year-old age
groups (98 centers in 23 countries), only the associations between
persistent symptoms andmean, maximum, andminimummonthly
vapor pressure were signiﬁcant. A positive within-country associ-
ation was also observed between the maximum monthly vegeta-
tion measurements and persistent symptom prevalence but only
among the 6- to 7-year-old age groups.
When the analysis was restricted to children with intermittent
or persistent rhinitis symptoms who also reported itchy-eye
symptoms in the last 12 months, risk estimates remained in the
same direction but were generally smaller and were not signiﬁcant
for 1 of the 10 between-country associations and 5 of the 8 within-
country associations observed for the 13- to 14-year-old age groups
(eTable 5). Within-country associations were robust to the adjust-
ment for air pollution (ie, particulate matter with aerodynamic
diameters <2.5 m/m and nitrogen dioxide) and mutual adjustment
for meteorologic and vegetation factors. Estimates for the between-
country associations were also generally similar, although a loss of
statistical signiﬁcance was occasionally observed (data not shown).
Discussion
Several spatial associations between climatic factors and the
prevalence of intermittent and persistent rhinitis symptoms were
observed in a nonrandomly selected group of centers and countries
that participated in ISAAC Phase Three. Our results suggest a gen-
eral positive association of mean monthly temperature and vapor
pressure (which were highly correlated, rs ¼ 0.925) and precipita-
tion, with symptom prevalence. This cross-sectional global study is
a ﬁrst step in assessing how climate change can affect allergic
rhinitis symptoms. However, the generalizability of the observed
associations and the inﬂuence of other factors not accounted for in
this analysis on the association between climate and rhinitis
remain unknown.
To account for the hierarchical nature of the data, we examined
between- and within-county effects (country- and center-level as-
sociations, respectively). Associations with intermittent rhinitis
Figure 1. World map showing the center prevalence of intermittent rhinitis symptoms for the centers with 13- to 14-year-olds.
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limited evidencewas observed at the center level. Persistent rhinitis
prevalence was only associated with climatic factors at the center
level. One explanation for these ﬁndings may be that intermittent
symptoms are more strongly associated with temporal changes
in certain allergens affected by climate (eg, pollens and molds),
whereas lifestyle factors have a greater inﬂuence on persistent
symptoms. Thus, we were able to detect the relatively strong
between-country associations for climate with intermittent symp-
tom prevalence but not with persistent symptom prevalence
because this latter association may be confounded by more
important causal lifestyle factors that differ by country. Differences
in sensitization patterns across areas are also likely to exist. Because
these factors are less likely to differ within countries, the potentially
weaker association for persistent symptom prevalence with cli-
matic factors may only be detectable in the within-country ana-
lyses, which are less likely inﬂuenced by unmeasured confounding.
Our ﬁnding of a positive association of temperature, vapor
pressure, and precipitationwith rhinitis symptoms has been in part
observed inprevious single- or limited-area studies,10,11,13 but others
report null ﬁndings.12,29e31 It is challenging to reconcile these pre-
vious studies with the current one because the effect of climate on
allergen distribution (and thus presumably rhinitis) likely varies
with local vegetation and geographical area.32 Furthermore, these
studies are based on data collected from adults, whereas the current
study focuses on children and teenagers. To the best of our knowl-
edge, there are only 2 multiarea studies on rhinitis. A study of 48Figure 2. World map showing the center prevalence of persistenEuropean centers conducted on adults concluded that climate can
account for signiﬁcant variability in (mostly asthma-related) respi-
ratory symptom prevalence, although hay fever was only associated
with temperature during the hottest month.33 Another study, and
the only one to include centers outside Europe and to study children,
uses data from ISAAC Phase One.14 In this study, climatic factors and
allergic rhinitis symptoms were not associated, although suggestive
evidence for asthma and atopic eczema was reported for Western
European centers. In general, worldwide associations were incon-
sistent. By contrast, the current study is based on a substantially
larger number of centers (222 centers in 94 countries and 144
centers in 81 countries were used in the current and previous
worldwide analyses for the 13- to 14-year-olds, respectively) and
examines intermittent and persistent rhinitis prevalences as out-
comes rather than any report of rhinitis in the last 12months. As the
prevalence of rhinitis symptoms has increased in most centers be-
tween the timing of the ISAAC Phase One (1992e1997) and ISAAC
Phase Three (2000e2003) surveys,34 associations with intermittent
and persistent rhinitis symptoms may be easier to detect in the
ISAAC Phase Three data. The current study is also the ﬁrst, to our
knowledge, to examine associations between vegetation and rhinitis
prevalence in a global context.
The mechanisms by which climatic factors may inﬂuence
rhinitis are unclear but may be indirect via changes in indoor fac-
tors, such as dampness, which are likely to affect the distribution of
indoor allergens, or via changes in pollen types, distributions, and
concentrations, a phenomenon well documented in previoust rhinitis symptoms for the centers with 13- to 14-year-olds.
Table 2
Correlations between modeled variables for the centers with 13- to 14-year-olds (222 centers)
Variable Period Median (IQR) Spearman correlation
Intermittent
rhinitis
Persistent
rhinitis
Mean
NDVI
Mean
temperature
Mean
precipitation
Mean vapor
pressure
Health outcome
Intermittent rhinitis w2000e2003 14.1 (9.7e20.0) e e 0.074 0.361a 0.223a 0.332a
Persistent rhinitis w2000e2003 13.7 (8.6e19.5) e e 0.105 0.195a 0.054 0.084
Economic/population
GNI per capitab 2003 2950 (1,483e13,070) 0.202a 0.526a 0.303a 0.441a 0.021 0.318a
Population density 2005 809 (297e2,779) 0.025 0.048 0.310a 0.222a 0.062 0.183a
Environmental factors
Mean NDVI,c NDVI units 2005 0.4 (0.3e0.5) e e e 0.058 0.422a 0.084
Mean temperature, oC 1991e2000 17.9 (12.1e24.4) e e e e 0.407a 0.925a
Mean precipitation, mm 1991e2000 81.7 (50.4e124.5) e e e e e 0.568a
Mean vapor pressure, hPa 1991e2000 14.1 (10.7e21.7) e e e e e e
Abbreviations: GNI, gross national income; IQR, interquartile range; NDVI, normalized difference vegetation index.
aP < .05.
bCorrelations with GNI per capita are with country-level variables (94 countries).
cOnly 215 centers had information on NDVI.
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mate assigned to one geographic coordinate is unlikely to accu-
rately reﬂect the vegetation of a whole area, we used the mean of 9
NDVI estimates, each assigned to a 0.07  0.07 square (area
coverage of approximately 59 km2). Most risk estimates obtained
were elevated, although all but one were nonsigniﬁcant, despite
moderate variation in NDVI units among countries (range of mean
country vegetation estimates was 0.44) and within countries (eg,
range of mean center vegetation estimates was 0.68 in Chile with 5
participating centers and 0.49 in Spain with 12 participating cen-
ters). Inclusion of interaction terms between vegetation and tem-
perature exposures yielded some signiﬁcant associations for
intermittent rhinitis (data not shown). We also examined whether
associations may be stronger among smaller countries where the
NDVI estimate is more likely to reﬂect exposures throughout theTable 3
Between-country associations for intermittent and persistent rhinitis prevalence with
94 countries)a
Country-level environmental factor Mean difference in country-level prevalen
Intermittent rhinitis
Temperature
Mean (10.4C) 0.59 (0.20 to 0.98)b
Maximum (4.6C) 0.33 (0.15 to 0.82)
Minimum (16.1C) 0.43 (0.15 to 0.71)b
SD (2.1C) 0.56 (1.62 to 0.49)
Maximal difference (12.5C) 0.36 (0.67 to -0.05)c
Precipitation
Mean (67.0 mm) 0.05 (0.01 to 0.09)c
Maximum (166.1 mm) 0.02 (0.01 to 0.04)c
Minimum (42.7 mm) 0 (0.07 to 0.07)
SD (51.5 mm) 0.09 (0.03 to 0.14)b
Maximal difference (137.8 mm) 0.03 (0.01 to 0.05)a
Vapor pressure
Mean (10.4 hPa) 0.60 (0.21 to 0.99)b
Maximum (8.6 hPa) 0.44 (0.07 to 0.81)c
Minimum (10.8 hPa) 0.55 (0.17 to 0.93)b
SD (2.0 hPa) 0.25 (1.24 to 1.74)
Maximal difference (4.9 hPa) 0.23 (0.69 to 0.23)
Vegetationd
Mean (0.1) 8.03 (8.75 to 24.81)
Maximum (0.1) 6.33 (8.54 to 21.20)
Minimum (0.1) 4.31 (13.52 to 22.14)
SD (0.02) 11.57 (41.84 to 64.98)
Maximal difference (0.1) 5.48 (13.14 to 24.11)
Abbreviation: CI, conﬁdence interval.
aAll models adjusted for center mean exposure of interest, center, and country mean po
bP < .01.
cP < .05.
dVegetation data only available for 215 centers in 87 countries.country. Only when the analysis was restricted to countries smaller
than 50,000 km2 (21 centers in 17 countries) was a positive
between-country association found between intermittent symp-
tom prevalence and the maximal difference and SD of monthly
vegetation estimates. Because it is well established that pollen can
disperse over large distances,35 it is possible that our ecologic study
design may not be ideal for assessing associations with vegetation,
which may be more heterogeneous over small areas. Furthermore,
using NDVI as a surrogate for vegetation did not allow us to
distinguish plant species of differing allergenicity.
An important strength of this study is the ability to examine
associations between and within countries using a multilevel
modeling approach. Examining between-country associations al-
lows the use of the entire data set, thereby taking full advantage of
the large number and exposure contrasts of the countriesenvironmental factors for the centers with 13- to 14-year-olds (222 centers in
ce (95% CI) per 100 children per 1-U increase in country-level exposure
Persistent rhinitis
0.02 (0.34 to 0.29)
0.10 (0.47 to 0.27)
0.02 (0.25 to 0.21)
0.05 (0.78 to 0.88)
0.07 (0.18 to 0.32)
0.01 (0.02 to 0.04)
0 (0.01 to 0.02)
0 (0.06 to 0.05)
0.01 (0.04 to 0.05)
0 (0.02 to 0.02)
0.17 (0.15 to 0.48)
0.18 (0.11 to 0.47)
0.12 (0.19 to 0.44)
0.75 (0.38 to 1.87)
0.23 (0.12 to 0.58)
9.45 (3.84 to 22.75)
7.98 (3.91 to 19.87)
8.48 (5.57 to 22.53)
19.32 (23.92 to 62.56)
3.51 (11.51 to 18.53)
pulation density, country gross national income per capita, and climate type.
Table 4
Within-country associations for intermittent and persistent rhinitis prevalence with environmental factors among countries with 2 or more centers per country for the centers
with 13- to 14-year-olds (165 centers in 37 countries)a
Center-level environmental factor Mean difference in center-level prevalence (95% CI) per 100 children per 1-U increase in center-level exposure
Intermittent rhinitis Persistent rhinitis
Temperature
Mean (10.7C) 0.43 (0.02 to 0.84)b 0.39 (0.03 to 0.76)b
Maximum (6.8C) 0.32 (0.05 to 0.68) 0.37 (0.05 to 0.70)b
Minimum (11.9C) 0.26 (0.10 to 0.62) 0.16 (0.16 to 0.49)
SD (2.6C) 0.63 (0.50 to 1.75) 0.71 (0.30 to 1.72)
Maximal difference (12.1C) 0.12 (0.28 to 0.52) 0.22 (0.13 to 0.58)
Precipitation
Mean (68.7 mm) 0.03 (0.06 to 0.01) 0.01 (0.04 to 0.03)
Maximum (162.9 mm) 0.01 (0.02 to 0.01) 0.01 (0.03 to 0)
Minimum (35.1 mm) 0.05 (0.11 to 0.01) 0 (0.05 to 0.06)
SD (58.5 mm) 0.01 (0.06 to 0.04) 0.04 (0.08 to 0)
Maximal difference (161.5 mm) 0 (0.02 to 0.02) 0.01 (0.03 to 0)
Vapor pressure
Mean (8.4 hPa) 0.22 (0.15 to 0.59) 0.37 (0.04 to 0.70)b
Maximum (10.1 hPa) 0.20 (0.08 to 0.49) 0.31 (0.06 to 0.56)b
Minimum (6.2 hPa) 0.25 (0.17 to 0.67) 0.39 (0.02 to 0.76)b
SD (2.4 hPa) 1.14 (0.06 to 2.21)b 1.32 (0.37 to 2.27)c
Maximal difference (5.7 hPa) 0.30 (0.10 to 0.71) 0.28 (0.09 to 0.64)
Vegetation
Mean (0.2) 1.25 (10.81 to 8.31) 2.89 (11.42 to 5.64)
Maximum (0.2) 0.40 (8.82 to 8.02) 0.25 (7.79 to 7.29)
Minimum (0.2) 2.93 (13.61 to 7.76) 5.47 (14.98 to 4.04)
SD (0.05) 0.75 (36.50 to 37.99) 7.53 (25.95 to 41.02)
Maximal difference (0.2) 3.19 (9.41 to 15.78) 6.94 (4.31 to 18.20)
Abbreviation: CI, conﬁdence interval.
aAll models adjusted for the country mean exposure of interest, center and country mean population density, country gross national income per capita, and climate type.
bP < .05.
cP < .01.
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stantial between-country differences were not captured by model
adjustments for GNI per capita, climate type, or air pollution, and
thus we cannot exclude the possibility that residual confounding
may be affecting the between-country associations. The differen-
tiation between intermittent and persistent symptoms is however
less likely to be affected by translation or awareness artifacts
attributable to language and culture, which often hinder interna-
tional comparisons of prevalence in ISAAC (and other
questionnaire-based studies). Nevertheless, it remains possible that
there may be some variation in the way the questionnaires were
completed or administered. Confounding, although still possible, is
less of a concern for the within-country associations because causal
factors are less likely to differ to the same degree within countries
as between countries. However, we did not account for individual
risk factors, a limitation common to all ecologic studies. Given that
only countries with 2 or more participating centers per country can
contribute to the within-country analysis, these results are hin-
dered by a lack of statistical power in terms of fewer centers and
smaller exposure variation. Finally, a possible limitation of this
study is that associations were not adjusted for multiple testing
because it is not clear that the different exposure metrics (eg, the
mean, maximum, minimum, SD, and maximal difference of tem-
perature) represent the same exposure, especially not worldwide,
and correcting for multiple testing can lead to conservative results
when exposures are highly correlated.
ISAAC, given its size and worldwide coverage, which spans
several different climate zones, is unique in its ability to assess the
associations considered in this report. The collection of data from
both 13- to 14-year-olds and 6- to 7-year-olds, using the stan-
dardized and validated ISAAC protocol and questionnaire, allowed
for replication of analyses. The direction of estimates was the same
for all signiﬁcant between-country associations with intermittent
symptoms and all but one within-country associations with
persistent symptoms. Given that symptom data were collected foreach month and therefore the period in days and weeks of each
rhinitis episode was not available, our persistent rhinitis deﬁnition
differs slightly from that proposed by the Allergic Rhinitis and Its
Impact on Asthma workshop group, which requires symptoms to
persist for more than 4 days per week and for more than 4
consecutive weeks.7 The outcome deﬁnitions used in this report
also deviate from those commonly used by ISAAC for allergic
rhinitis (rhinoconjunctivitis), which requires a positive report of
both nose symptoms and itchy eyes.1 Information on itchy eyes was
only collected for one time point covering anytime in the last 12
months. A sensitivity analysis that considered intermittent or
persistent symptoms and itchy eyes anytime in the last 12 months
as alternate outcomes yielded similar results, especially for the
between-country associations. Associations for both intermittent
and persistent symptoms were stronger for children who reported
that their nose problems interfered with daily activities “a mod-
erate amount” and a “lot” compared with those who answered “not
at all” or “no answer provided,”whichmay suggest that climate not
only inﬂuences the prevalence of disease but also the severity of
symptoms (data not shown). However, we were unable to replicate
this ﬁnding using the more stringent severe symptom deﬁnition
normally used by ISAAC (which identiﬁes severe symptoms as
those that interfere with daily activities “a lot”) because the center
prevalences of severe symptoms were quite low. As with all
questionnaire-based data, recall bias is possible. Symptom reports
were highest in the months before and after the month the surveys
were administered. We do not anticipate that this would affect the
results because the outcomes considered were not month speciﬁc.
Caution should be applied in interpretation of these data as
representative of world prevalence because the centers and coun-
tries participating in ISAAC were not randomly selected. Finally,
although during the design of this analysis we attempted to use
data from the same period, not all data sets overlap temporally.
In conclusion, several between- and within-country spatial as-
sociations between climatic factors (temperature, vapor pressure,
E. Fuertes et al. / Ann Allergy Asthma Immunol 113 (2014) 386e392392and precipitation) and the prevalence of intermittent and persistent
rhinitis symptoms were observed in this cross-sectional global
analysis. These results provide suggestive evidence that climate
inﬂuences the prevalence of rhinitis symptoms. Although not
conclusive, our results represent a ﬁrst step in investigating how
future climate change may affect rhinitis symptom prevalence.
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eTable 1
Descriptive statistics for the centers with 13- to 14-year-olds
Country Center No. of children Intermittent rhinitis prevalence Persistent rhinitis prevalence
Africa
Algeria West Algiers 4,203 0.07 27.96
Cameroon Yaounde 2,983 0.07 25.54
Congo Brazzaville 1,012 49.51 6.42
Ethiopia Addis Ababa 3,195 19.69 5.67
Gabon Port-Gentil 3,166 36.13 0
Kenya Eldoret 3,289 27.79 5.66
Nairobi 3,023 21.63 12.44
Morocco Casablanca 1,777 21.72 28.59
Marrakech 1,689 20.07 11.84
Benslimane 1,254 14.51 7.89
Boulmene 1,008 32.04 5.85
Nigeria Ibadan 3,142 35.65 0
République Democratique du Congo Kinshasa 2,930 14.71 3.72
Reunion Island Reunion Island 2,362 19.26 20.58
South Africa Cape Town 5,037 25.99 18.60
Polokwane 4,660 39.94 8.71
Sudan Khartoum 2,896 8.91 4.39
Togo Lome 3,090 21.17 11.62
Tunisia Grand Tunis 6,119 40.42 18.35
Sousse 3,042 45.40 18.28
Asia-Paciﬁc
China Beijing 3,530 0.48 28.33
Guangzhou 3,514 14.34 29.00
Tibet 2,878 0.87 3.41
Tong Zhou 3,542 4.15 6.72
Wulumuqi 3,884 8.32 18.95
Hong Kong Hong Kong 3,321 13.91 26.80
Indonesia Bali 2,569 26.00 5.10
Bandung 2,826 11.92 5.87
Semarang 2,435 10.27 4.31
Japan Fukuoka 2,520 15.40 27.98
Tochigi 4,466 3.56 26.76
Malaysia Alor Setar 2,941 24.18 17.68
Klang Valley 3,025 15.27 21.79
Kota Bharu 2,989 27.57 6.96
Philippines Metro Manila 3,658 6.83 3.66
South Korea Provincial Korea 7,375 9.26 19.43
Seoul 2,888 9.38 17.73
Taiwan Taipei 6,378 8.97 32.08
Taoyuan 3,190 14.83 27.18
Thailand Bangkok 4,669 24.54 33.78
Chantaburi 2,901 28.82 18.58
Chiang Mai 3,538 15.72 31.85
Chiangrai 1,809 12.38 15.15
Khon Kaen 3,410 17.30 22.84
Nakorn Pathom 6,975 16.72 12.40
Vietnam Ho Chi Minh City 4,240 39.15 25.54
Eastern Mediterranean
Egypt Cairo 3,047 3.48 1.35
Iran Birjand 2,829 12.12 8.62
Rasht 3,004 0.37 25.60
Tehran 3,119 10.52 12.95
Zanjan 2,805 14.15 6.95
Jordan Amman 2,447 15.53 4.54
Kuwait Kuwait 2,882 19.99 6.14
Malta Malta 4,136 16.20 26.04
Pakistan Islamabad 4,069 13.03 21.82
Karachi 2,999 11.64 10.87
Palestine North Gaza 3,627 14.09 1.08
Ramallah 3,929 10.79 1.99
Sultanate of Oman Al-Khod 3,747 20.12 5.47
Syrian Arab Republic Aleppo 3,063 4.70 6.33
Lattakia 3,010 5.22 3.92
Tartous 2,995 1.64 1.50
Indian subcontinent
India Bangalore 3,440 16.57 8.95
Bikaner 3,059 22.20 19.75
Chandigarh 3,122 14.64 6.47
Davangere 2,945 0.58 9.95
Jaipur 3,607 29.55 8.34
Lucknow 3,000 28.77 11.80
Ludhiana 3,108 24.00 18.89
Chennai 2,181 7.79 1.65
Mumbai 1,829 4.70 3.34
Nagpur 4,150 5.20 4.46
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eTable 1 (continued )
Country Center No. of children Intermittent rhinitis prevalence Persistent rhinitis prevalence
New Delhi 3,469 12.19 13.69
Pimpri 3,128 1.79 0.74
Sri Lanka Sri Lanka 3,717 17.73 6.91
Latin America
Argentina Córdoba 3,445 14.72 23.08
Neuquén 3,172 18.13 19.83
Rosario City 3,099 11.52 11.55
Salta 3,000 15.90 21.73
Bolivia Santa Cruz 3,257 31.29 11.30
Brazil Aracaju 3,043 24.71 9.53
Belo Horizonte 3,088 20.95 7.71
Brasília 3,009 23.63 11.43
Caruaru 3,026 18.21 9.25
Curitiba 3,628 8.68 14.72
Feira de Santana 1,732 28.29 13.28
Itajaí 2,737 15.93 8.62
Maceió 2,745 12.68 12.09
Manaus Amazonas 3,009 15.29 6.68
Nova Iguaçu 3,185 11.65 4.27
Passo Fundo 2,949 18.51 12.55
Porto Alegre 3,007 18.52 14.57
Recife 2,865 0.28 31.13
Rural Santa Maria 3,057 18.29 6.48
Salvador 3,020 19.50 27.28
Santa Maria 3,065 17.32 8.42
Santo Andre 3,232 0.03 25.77
São Paulo 3,161 13.67 11.80
São Paulo West 3,181 17.73 14.05
Vitória da Conquista 1,679 30.49 19.54
Chile Calama 1,618 18.73 17.06
Chiloe 3,000 18.40 16.40
Punta Arenas 3,044 0.43 26.87
South Santiago 3,026 18.31 18.54
Valdivia 3,105 16.55 25.44
Colombia Barranquilla 3,204 36.11 15.79
Bogotá 3,830 23.94 15.56
Cali 3,100 30.45 14.06
Costa Rica Costa Rica 2,436 28.94 29.72
Cuba La Habana 3,026 16.23 17.32
Ecuador Guayaquil 3,082 20.12 13.95
Quito 3,014 23.56 12.14
El Salvador San Salvador 3,260 40.95 10.34
Honduras San Pedro Sula 2,675 33.16 7.07
Mexico Ciudad de México (1) 3,891 26.21 13.03
Ciudad de México (3) 3,474 26.11 4.35
Ciudad de México (4) 2,662 29.56 7.89
Ciudad Victoria 3,122 19.25 13.45
Cuernavaca 1,431 8.67 7.69
Mérida 3,019 25.44 10.40
Mexicali Valley 2,988 30.86 9.40
Monterrey 3,006 18.76 10.91
Toluca 3,021 5.96 3.08
Villahermosa 3,109 25.96 13.70
Nicaragua Managua 3,263 33.56 9.99
Panama David-Panamá 3,183 21.05 14.58
Paraguay Asunción 3,000 44.90 30.87
Peru Lima 3,022 0.10 17.97
Uruguay Montevideo 3,177 7.15 16.18
Paysandú 1,738 7.71 10.87
Venezuela Caracas 3,000 14.07 25.30
North America
Barbados Barbados 2,498 9.53 7.69
Canada Vancouver 2,853 14.72 22.99
Trinidad and Tobago St Augustine 3,512 11.10 22.61
Tobago 1,464 11.89 19.54
USA Sarasota 1,245 9.96 18.15
Seattle 2,422 15.32 17.22
Northern and Eastern Europe
Albania Tiranë 2,983 12.67 3.96
Bulgaria Soﬁa 1,926 12.51 8.88
Croatia Rijeka 2,194 8.34 8.43
Estonia Tallinn 3,603 12.13 12.96
Finland Kuopio County 3,051 13.01 27.56
Former Yugoslav Republic of Macedonia Skopje 3,026 8.66 14.71
Georgia Kutaisi 2,650 7.17 6.94
Hungary Svábhegy 4,219 3.48 12.97
Szeged 2,889 3.98 9.69
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eTable 1 (continued )
Country Center No. of children Intermittent rhinitis prevalence Persistent rhinitis prevalence
Kyrgyzstan Balykchi 1,382 2.10 13.39
Bishkek 5,048 3.68 11.51
Jalalabat 2,404 22.42 6.03
Latvia Riga 1,283 8.81 9.74
Lithuania Kaunas 2,723 8.01 9.33
Panevezys 1,187 14.15 19.63
Siauliai 3,516 12.71 12.37
Poland Krakow 2,545 9.59 25.85
Poznan 1,875 10.72 25.97
Romania Cluj 3,019 15.07 21.00
Russia Novosibirsk 3,769 16.95 15.47
Serbia and Montenegro Belgrade 3,228 11.59 9.32
Nis 1,207 18.64 13.67
Novi Sad 1,171 7.94 6.58
Podgorica 1,014 10.85 7.89
Sombor 1,105 11.76 3.08
Sweden Linköping 2,679 3.84 15.45
Ukraine Kharkiv 2,428 2.59 6.26
Rural Kharkiv 3,968 20.29 4.36
Oceania
Australia Melbourne 2,192 16.42 20.39
Cook Islands Rarotonga 445 24.27 2.47
Fiji Suva 3,093 31.52 10.67
Kingdom of Tonga Nuku’alofa 2,671 0.04 17.48
New Zealand Auckland 2,870 20.63 19.79
Bay of Plenty 1,976 13.56 17.26
Christchurch 3,116 11.07 17.36
Nelson 2,305 10.07 19.70
Wellington 3,050 16.95 28.72
Niue Niue Island 79 22.78 18.99
Nouvelle Caledonie Nouvelle Caledonie 7,247 24.49 11.77
Polynesie Francaise Polynesie Francaise 4,289 20.73 10.89
Samoa Apia 2,986 11.82 2.18
Tokelau Tokelau 66 34.85 13.64
Western Europe
Austria Urfahr-Umgebung 1,439 7.44 11.88
Belgium Antwerp 3,250 9.72 25.69
Channel Islands Guernsey 1,248 12.74 18.91
Jersey 773 11.64 16.30
Germany Münster 4,132 10.91 19.46
Isle of Man Isle of Man 1,716 16.84 21.45
Italy Bari 1,287 18.34 18.57
Colleferro-Tivoli 1,361 9.63 10.14
Cosenza 925 6.49 8.76
Emilia-Romagna 1,347 13.29 19.90
Empoli 1,229 15.79 15.30
Firenze 1,383 12.65 18.51
Mantova 1,114 11.13 23.07
Milano 1,410 10.85 22.34
Palermo 1,221 11.96 18.18
Roma 1,325 8.83 26.94
Siena 1,082 11.74 24.77
Torino 1,180 12.37 21.36
Trento 1,311 4.35 11.82
The Netherlands The Netherlands 6,896 8.45 18.16
Portugal Coimbra 1,177 10.79 11.21
Funchal 3,161 10.16 10.09
Lisbon 3,024 12.10 15.31
Portimao 1,109 0.09 20.02
Porto 3,336 14.81 15.08
Republic of Ireland Republic of Ireland 3,089 13.05 20.78
Spain A Coruña 2,979 14.84 19.54
Almeria 4,051 8.49 14.76
Asturias 4,184 16.32 18.57
Barcelona 3,066 9.65 12.26
Bilbao 3,401 8.17 14.61
Cartagena 3,998 14.76 15.68
Castellón 4,024 11.16 19.38
Madrid 2,652 12.14 14.86
Pamplona 2,932 9.89 13.27
San Sebastián 1,195 10.88 13.39
Valencia 3,132 12.77 11.11
Valladolid 2,944 15.18 15.29
United Kingdom North Thames 2,356 16.38 20.12
Scotland 4,662 12.91 22.31
South Thames 2,432 15.79 17.56
Surrey-Sussex 5,082 12.99 18.91
Wales 2,501 13.39 21.63
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eTable 2
Descriptive statistics for the centers with 6- to 7-year-olds
Country Center No. of children Intermittent rhinitis prevalence Persistent rhinitis prevalence
Africa
Nigeria Ibadan 2,396 16.65 0
South Africa Polokwane 3,480 26.15 4.57
Asia-Paciﬁc
Hong Kong Hong Kong 4,448 13.02 23.40
Indonesia Bandung 2,503 12.74 2.36
Japan Fukuoka 2,958 7.98 18.09
Malaysia Alor Setar 3,786 10.17 3.86
Klang Valley 3,044 9.59 4.86
Kota Bharu 3,110 11.32 3.83
South Korea Provincial Korea 4,258 6.95 16.67
Seoul 1,760 7.05 18.58
Taiwan Taipei 4,832 6.21 31.42
Taoyuan 3,293 8.78 30.31
Thailand Bangkok 4,209 19.51 22.62
Chantaburi 3,321 18.85 14.39
Chiang Mai 3,106 15.04 13.17
Chiangrai 1,677 10.73 12.10
Khon Kaen 2,658 11.96 18.81
Nakorn Pathom 1,821 12.85 12.03
Vietnam Ho Chi Minh City 3,879 19.49 15.49
Eastern Mediterranean
Iran Birjand 2,693 7.98 4.68
Rasht 3,057 0.10 30.75
Tehran 3,008 3.36 4.89
Zanjan 2,777 17.21 8.64
Jordan Amman 2,598 11.97 4.35
Malta Malta 3,795 9.01 16.02
Pakistan Islamabad 3,966 5.77 12.36
Karachi 2,113 6.39 5.92
Palestine North Gaza 3,575 11.78 2.66
Ramallah 3,754 8.98 2.66
Sultanate of Oman Al-Khod 4,130 10.94 3.95
Syrian Arab Republic Lattakia 2,373 3.75 5.44
Tartous 2,734 7.68 10.02
Indian subcontinent
India Davangere 3,043 0.82 7.59
Jaipur 2,545 17.25 9.12
Lucknow 3,000 15.07 7.57
Ludhiana 3,225 9.64 7.26
Mumbai 1,833 3.66 3.76
Nagpur 4,294 3.89 3.31
New Delhi 3,706 7.37 9.15
Pimpri 3,838 4.22 3.31
Sri Lanka Sri Lanka 3,345 10.40 7.41
Latin America
Argentina Neuquén 1,930 11.35 16.48
Rosario City 2,952 6.30 9.79
Brazil Aracaju 2,443 13.10 8.64
Itajaí 1,511 11.05 9.79
Maceió 1,990 11.96 10.10
Manaus Amazonas 3,011 11.19 6.14
Nova Iguaçu 3,249 14.40 10.19
Salvador 1,069 11.51 26.47
Santo Andre 2,167 0.14 29.72
São Paulo 3,047 11.68 14.83
São Paulo West 3,312 16.06 13.35
Chile Punta Arenas 3,052 0.16 24.02
South Santiago 3,075 7.97 18.05
Valdivia 3,183 5.94 21.77
Colombia Barranquilla 3,209 17.23 13.24
Bogotá 3,256 15.14 14.28
Cali 3,005 20.30 14.08
Costa Rica Costa Rica 3,234 29.00 33.21
Cuba La Habana 1,803 13.59 20.91
Ecuador Quito 3,055 8.84 5.70
El Salvador San Salvador 1,365 27.69 10.40
Honduras San Pedro Sula 1,907 20.35 7.24
Mexico Ciudad de México (1) 3,205 33.35 9.64
Ciudad de México (3) 3,493 41.80 6.44
Ciudad Victoria 2,603 11.64 9.80
Cuernavaca 2,579 9.00 10.74
Mérida 2,896 16.23 19.68
Mexicali Valley 2,568 14.33 12.77
Monterrey 3,030 10.40 10.59
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eTable 2 (continued )
Country Center No. of children Intermittent rhinitis prevalence Persistent rhinitis prevalence
Toluca 3,235 10.39 7.54
Villahermosa 2,678 20.43 13.18
Nicaragua Managua 3,286 18.62 15.61
Panama David-Panamá 2,942 20.90 14.41
Uruguay Paysandú 1,512 6.75 11.11
Venezuela Caracas 2,999 8.64 21.94
North America
Barbados Barbados 2,759 5.15 4.49
Canada Saskatoon 1,255 3.43 21.35
Northern and Eastern Europe
Albania Tiranë 2,896 8.87 5.18
Bulgaria Soﬁa 1,181 6.01 5.50
Croatia Rijeka 1,633 3.74 12.80
Estonia Tallinn 2,385 4.99 7.59
Georgia Kutaisi 2,666 3.19 5.14
Hungary Svábhegy 2,451 1.75 10.53
Kyrgyzstan Bishkek 3,146 2.29 7.95
Jalalabat 1,664 14.72 7.39
Lithuania Kaunas 2,772 8.30 11.22
Panevezys 1,176 7.65 13.69
Siauliai 1,341 8.65 11.93
Poland Krakow 2,497 4.45 25.11
Poznan 1,999 3.75 22.41
Russia Novosibirsk 2,730 9.78 11.10
Serbia and Montenegro Belgrade 1,932 8.07 10.97
Nis 1,002 3.29 9.58
Novi Sad 1,044 6.51 6.99
Sombor 1,029 3.98 5.93
Sweden Linköping 2,089 1.58 10.29
Ukraine Kharkiv 1,950 2.31 6.21
Rural Kharkiv 3,000 15.57 4.87
Oceania
Australia Melbourne 2,968 5.63 18.09
New Zealand Auckland 3,541 6.07 16.77
Bay of Plenty 2,150 4.65 18.00
Christchurch 3,315 3.59 19.16
Nelson 1,867 3.00 15.05
Niue Niue Island 47 12.77 6.38
Western Europe
Austria Kärnten 4,847 2.58 7.49
Urfahr-Umgebung 2,029 2.61 9.46
Belgium Antwerp 5,645 3.21 12.31
Germany Münster 3,830 2.61 12.72
Greece Thessaloniki 1,228 10.26 4.97
Isle of Man Isle of Man 1,096 2.65 13.14
Italy Bari 1,943 7.05 12.09
Colleferro-Tivoli 1,143 2.97 12.51
Emilia-Romagna 2,265 4.06 12.54
Empoli 1,152 4.17 12.15
Firenze 1,036 4.15 13.32
Mantova 1,288 3.65 12.27
Milano 2,249 4.36 13.34
Roma 2,224 4.27 14.61
Torino 2,361 4.62 12.88
Trento 2,359 2.67 9.71
Portugal Funchal 1,819 8.80 11.16
Lisbon 2,477 8.48 15.46
Portimao 1,069 0 21.33
Porto 2,464 8.16 11.73
Spain A Coruña 3,016 6.60 13.66
Almeria 3,349 5.32 11.38
Asturias 3,193 7.23 12.18
Barcelona 3,002 2.73 5.26
Bilbao 3,157 5.99 10.96
Cartagena 2,948 5.90 9.77
Castellón 3,915 3.32 10.19
Madrid 2,347 10.01 11.55
Pamplona 3,176 3.21 6.77
Valencia 3,398 6.00 7.56
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eTable 3
Between-country associations for intermittent and persistent rhinitis prevalence with environmental factors for the centers with 6- to 7-year-olds (132 centers in 57
countries)a
Country-level environmental factor Average difference in country-level prevalence (95% CI) per 100 children per 1-U increase in country-level exposure
Intermittent rhinitis Persistent rhinitis
Temperature
Mean (10.6C) 0.28 (0.07 to 0.64) 0.09 (0.30 to 0.47)
Maximum (5.3C) 0.06 (0.33 to 0.46) 0.17 (0.65 to 0.31)
Minimum (16.8C) 0.22 (0.03 to 0.47) 0.11 (0.16 to 0.39)
SD (2.1C) 0.24 (1.04 to 0.57) 0.52 (1.46 to 0.42)
Maximal difference (13.4C) 0.32 (0.56 to 0.07)b 0.09 (0.37 to 0.18)
Precipitation
Mean (67.7 mm) 0.03 (0 to 0.07) 0.02 (0.02 to 0.06)
Maximum (201.2 mm) 0.02 (0 to 0.04)b 0.01 (0.01 to 0.03)
Minimum (28.6 mm) 0.04 (0.10 to 0.02) 0.01 (0.08 to 0.07)
SD (64.6 mm) 0.09 (0.04 to 0.14)c 0.04 (0.02 to 0.10)
Maximal difference (182.99 mm) 0.03 (0.01 to 0.05)c 0.02 (0.01 to 0.04)
Vapor pressure
Mean (11.1 hPa) 0.25 (0.07 to 0.57) 0.18 (0.19 to 0.54)
Maximum (9.8 hPa) 0.12 (0.16 to 0.40) 0.04 (0.30 to 0.38)
Minimum (10.6 hPa) 0.31 (0 to 0.62) 0.19 (0.16 to 0.55)
SD (1.9 hPa) 0.02 (1.05 to 1.09) 0.37 (1.68 to 0.94)
Maximal difference (5.4 hPa) 0.30 (0.61 to 0.01) 0.11 (0.50 to 0.28)
Vegetationd
Mean (0.1) 3.90 (10.82 to 18.62) 14.23 (2.35 to 30.81)
Maximum (0.2) 4.84 (8.09 to 17.78) 10.06 (4.81 to 24.94)
Minimum (0.1) 0.81 (14.67 to 16.29) 13.98 (3.39 to 31.35)
SD (0.03) 3.62 (39.50 to 46.74) 11.00 (37.10 to 59.10)
Maximal difference (0.1) 4.90 (9.54 to 19.33) 1.06 (15.70 to 17.82)
Abbreviation: CI, conﬁdence interval.
aAll models adjusted for center mean exposure of interest, center and country mean population density, country gross national income per capita, and climate type.
bP < .05.
cP < .01.
dVegetation data only available for 131 centers in 56 countries.
eTable 4
Within-country associations for intermittent and persistent rhinitis prevalence with environmental factors among countries with 2 or more centers per country for the centers
With 6- to 7-year-olds (98 centers in 23 countries)a
Center-level environmental factor Mean difference in center-level prevalence (95% CI) per 100 children per 1-U increase in center-level exposure
Intermittent rhinitis Persistent rhinitis
Temperature
Mean (10.9C) 0.37 (0.85 to 0.10) 0.42 (0.01 to 0.84)
Maximum (7.2C) 0.33 (0.72 to 0.07) 0.32 (0.02 to 0.67)
Minimum (13.4C) 0.32 (0.77 to 0.13) 0.32 (0.09 to 0.74)
SD (2.4C) 0.16 (1.56 to 1.24) 0.48 (0.77 to 1.72)
Maximal difference (12.7C) 0.02 (0.48 to 0.43) 0.13 (0.28 to 0.55)
Precipitation
Mean (57.2 mm) 0.01 (0.04 to 0.05) 0.01 (0.03 to 0.05)
Maximum (177.7 mm) 0 (0.02 to 0.02) 0 (0.02 to 0.01)
Minimum (30.2 mm) 0.01 (0.08 to 0.06) 0 (0.06 to 0.06)
SD (68.5 mm) 0 (0.04 to 0.05) 0.01 (0.05 to 0.03)
Maximal difference (172.05 mm) 0 (0.02 to 0.02) 0 (0.02 to 0.01)
Vapor pressure
Mean (9.0 hPa) 0.38 (0.79 to 0.03) 0.42 (0.05 to 0.79)b
Maximum (11.4 hPa) 0.30 (0.62 to 0.03) 0.32 (0.03 to 0.61)b
Minimum (7.9 hPa) 0.25 (0.71 to 0.20) 0.45 (0.04 to 0.86)b
SD (2.2 hPa) 0.09 (1.38 to 1.20) 0.63 (0.50 to 1.77)
Maximal difference (5.7 hPa) 0.17 (0.66 to 0.31) 0.25 (0.19 to 0.69)
Vegetation
Mean (0.1) 9.05 (19.66 to 1.55) 8.37 (1.04 to 17.77)
Maximum (0.2) 7.58 (17.01 to 1.85) 8.81 (0.53 to 17.09)b
Minimum (0.1) 8.11 (19.77 to 3.55) 6.90 (3.52 to 17.31)
SD (0.05) 30.47 (74.18 to 13.25) 33.08 (5.55 to 71.71)
Maximal difference (0.2) 5.49 (20.63 to 9.66) 11.09 (2.22 to 24.40)
Abbreviation: CI, conﬁdence interval.
aAll models adjusted for the country mean exposure of interest, center and country mean population density, country gross national income per capita, and climate type.
bP < .05.
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eTable 5
Between- and within-country associations between environmental factors and the prevalence of intermittent rhinitis and itchy eyes and persistent rhinitis and itchy eyes for
the centers with 13- to 14-year-oldsa
Environmental factor Mean difference in country-level prevalence (95% CI) per 100
children per 1-U increase in country-level exposureb
Mean difference in center-level prevalence (95% CI) per 100
children per 1-U increase in center-level exposurec
Intermittent rhinitis and itchy eyes Persistent rhinitis and itchy eyes Intermittent rhinitis and itchy eyes Persistent rhinitis and itchy eyes
Temperature
Mean 0.36 (0.16 to 0.56)d 0.03 (0.14 to 0.21) 0.23 (0.05 to 0.42)e 0.13 (0.07 to 0.32)
Maximum 0.17 (0.09 to 0.43) 0.07 (0.27 to 0.14) 0.21 (0.04 to 0.38)e 0.15 (0.02 to 0.32)
Minimum 0.27 (0.13 to 0.41)d 0.03 (0.10 to 0.16) 0.14 (0.03 to 0.30) 0 (0.18 to 0.17)
SD 0.60 (1.15 to 0.06)e 0.21 (0.67 to 0.25) 0.49 (0.02 to 1.01) 0.61 (0.08 to 1.13)e
Maximal difference 0.25 (0.40 to 0.09)d 0.04 (0.18 to 0.10) 0.10 (0.08 to 0.28) 0.18 (0 to 0.37)
Precipitation
Mean 0.02 (0 to 0.04)e 0 (0.01 to 0.02) 0.02 (0.04 to 0)e 0.01 (0.03 to 0.01)
Maximum 0.01 (0 to 0.02)e 0 (0.01 to 0.01) 0 (0.01 to 0) 0.01 (0.02 to 0)
Minimum 0 (0.03 to 0.04) 0.01 (0.02 to 0.04) 0.03 (0.06 to 0)e 0.01 (0.03 to 0.02)
SD 0.04 (0.01 to 0.07)d 0 (0.03 to 0.03) 0.01 (0.03 to 0.02) 0.02 (0.04 to 0)
Maximal difference 0.02 (0 to 0.03) 0 (0.01 to 0.01) 0 (0.01 to 0.01) 0.01 (0.02 to 0)
Vapor pressure
Mean 0.33 (0.14 to 0.53)d 0.11 (0.07 to 0.28) 0.11 (0.06 to 0.28) 0.10 (0.07 to 0.28)
Maximum 0.24 (0.04 to 0.43)e 0.09 (0.07 to 0.25) 0.11 (0.02 to 0.24) 0.10 (0.03 to 0.24)
Minimum 0.32 (0.13 to 0.51)d 0.10 (0.07 to 0.28) 0.15 (0.04 to 0.35) 0.13 (0.06 to 0.33)
SD 0 (0.80 to 0.80) 0.25 (0.39 to 0.88) 0.62 (0.13 to 1.11)e 0.60 (0.09 to 1.10)e
Maximal difference 0.19 (0.44 to 0.05) 0.03 (0.17 to 0.23) 0.14 (0.05 to 0.32) 0.11 (0.08 to 0.30)
Vegetation
Mean 6.22 (2.66 to 15.10)f 6.00 (1.36 to 13.36)f 0.74 (5.17 to 3.70) 2.56 (7.03 to 1.91)
Maximum 3.18 (4.70 to 11.05)f 4.22 (2.37 to 10.81)f 0.28 (4.18 to 3.62) 0.73 (4.69 to 3.24)
Minimum 6.83 (2.65 to 16.32)f 6.39 (1.39 to 14.18)f 1.39 (6.33 to 3.56) 4.33 (9.30 to 0.63)
SD 3.19 (31.33 to 24.95)f 6.49 (17.42 to 30.40)f 0.49 (16.75 to 17.73) 3.59 (14.00 to 21.18)
Maximal difference 2.28 (12.17 to 7.60)f 0.19 (8.52 to 8.14)f 1.26 (4.57 to 7.09) 4.31 (1.59 to 10.22)
Abbreviation: CI, conﬁdence interval.
aAll models adjusted for center mean exposure of interest (for between-country associations) or countrymean exposure of interest (for within-country associations), as well as
the center and country mean population density, country gross national income per capita, and climate type.
bOn the basis of data from 222 centers in 94 countries.
cOn the basis of data from 165 centers in 37 countries.
dP < .01.
eP < .05.
fVegetation data only available for 215 centers in 87 countries.
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